WASHINGTON, March 11 /PRNewswire-USNewswire/ -- Following is the daily
"Profile America" feature from the U.S. Census Bureau:
TUESDAY, MARCH 11: FLU EPIDEMIC'S 90TH
Profile America -- Tuesday, March 11th. One of the most devastating
public health crises of modern times hit the U.S. on this day 90 years ago
and experts are still studying it, hoping to head off a similar global
pandemic. The first cases were reported among soldiers at Fort Riley,
Kansas, just back from fighting in Europe. Called the "Spanish influenza,"
the virus moved quickly, and in October, the worst month, 195,000 Americans
perished. By 1920, nearly one-in-four Americans had suffered from this
strain of the flu, killing a half million of them. Worldwide, some 22
million people died. Even less dramatic forms of the disease are deadly.
Each year, nearly 60,000 Americans die of the flu and pneumonia. You can
find these and more facts about America from the U.S. Census Bureau on the
Web at http://www.census.gov.
Profile America is produced by the Public Information Office of the
U.S. Census Bureau. These daily features are available as produced segments
ready to air on a monthly CD or on Internet at http://www.census.gov (look
under the "Newsroom" button). For further information, contact Rick Reed at
+1-301-763-2812, fax at +1-301-457-3670, or e-mail at rreed(At)census.gov.
'/>"/>SOURCE U.S. Census Bureau Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 Related medicine technology :1.
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy2.
New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy3.
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV4.
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies5.
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting6.
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)7.
Voices to Unite in Los Angeles for 6,000 Children Orphaned Daily8.
European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection9.
Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial10.
CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients11.
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium